Check out the strongest names from our latest 2 to 100 Club scan. ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
Wednesday, November 26, 2025 |
|
|
Own the Best Stocks The way I've learned, the only way to make sure you own the best stocks is to buy the best stocks. We're not here to get stuck in one theme or sector just because we think it'll do well. The key is adapting quickly and rotating money where it's being treated best. Lately, healthcare — and more specifically, biotech — has been topping every leadership scan, continuing to rip higher. Here's the Biotech Clinical Trials ETF $BBC, soaring to fresh multi-year highs and completing a massive reversal base |
This ETF holds some of the smallest, riskiest, most speculative names in the market — and they're the ones leading the charge higher. This has been one of the most bullish pieces of evidence during an otherwise messy tape over the past couple weeks. There's nothing bearish about biotech making new highs. As long as BBC stays above its breakout level near 32, I'll keep hunting for long setups in this space. And speaking of leadership — our latest 2 to 100 Club report dropped this morning. This scan tracks the strongest growth stocks as they move from $2B and rolling off near $30B — the stocks we believe have the potential to reach $100B and become tomorrow's mega caps. Not surprisingly, this week's list is packed with biotech names. |
We publish this scan every Wednesday, and today we're buying one of the names from that table for ASC Premium members. Join ASC Premium today and take advantage of our special Thanksgiving discount — totally risk-free. Cheers, Alfonso De Pablos, CMT Director of Research, All Star Charts |
Alfonso De Pablos, CMT | Director of Research, All Star Charts |
|
|
All Star Charts emails are a financial publication of general circulation and only offers impersonal advice, not tailored to individual needs of a specific client or group. Any comments or statements made herein do not necessarily reflect those of All Star Charts or its affiliates (collectively, "All Star Charts") and do not constitute buy or sell recommendations. Unless specifically indicated, this message is not an official confirmation of any transaction. The contents of any email communications to or from All Star Charts may be monitored or reviewed at All Star Charts's discretion. All Star Charts accepts no responsibility for any loss or damage arising in any way from the use of this transmission and any attachments; it is the responsibility of the recipient to ensure that they are virus free. If you reply to this email, please note that we are a public investor and do not want any material non-public information. We do not agree to keep confidential any information you provide and do not agree to any restrictions on our trading activity, except pursuant to a written confidentiality agreement executed by All Star Charts. |
Want to change how you receive these emails? You can manage your preferences here unsubscribe. © 2025 All Star Charts 624 Broadway, Suite 405 San Diego, CA 92101 |
All Star Charts 624 Broadway Suite 405 San Diego, CA 92101 |
|
|
|